Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting

Roche today announced that it will present data from across its broad cancer immunotherapy development programme, including approved and investigational medicines, during the American Association for Cancer Research (AACR) Annual Meeting from 14 April to 18 April in Chicago, IL, United States. More than 42 abstracts have been accepted, including five “late breakers” and seven oral presentations.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news